IDEAYA Biosciences (IDYA) Share-based Compensation (2018 - 2026)

IDEAYA Biosciences has disclosed Share-based Compensation across 9 years of filings, most recently posting $14.5 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $14.5 million, up 41.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.4 million (up 30.37% YoY), and the FY2025 annual result was $46.1 million, up 32.72% from the prior year.
• Share-based Compensation came in at $14.5 million for Q1 2026 at IDEAYA Biosciences, up from $11.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $14.5 million in Q1 2026 to a low of $2.6 million in Q1 2022.
• The 5-year median for Share-based Compensation is $6.3 million (2024), against an average of $7.4 million.
• Across the five-year window, Share-based Compensation surged 105.75% in 2024 and increased 21.92% in 2025, its largest moves.
• IDEAYA Biosciences' Share-based Compensation stood at $3.0 million in 2022, then jumped by 61.28% to $4.8 million in 2023, then jumped by 97.69% to $9.5 million in 2024, then gained by 24.33% to $11.8 million in 2025, then rose by 23.26% to $14.5 million in 2026.
• The last three Share-based Compensation figures came in at $14.5 million (Q1 2026), $11.8 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.